Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials

Renee Bouley; Derong Ding; Zhihong Peng; Maria Bastian; Elena Lastochkin; Wei Song; Mark A. Suckow; Valerie A. Schroeder; William R. Wolter; Shahriar Mobashery; Mayland Chang

doi:10.1021/acs.jmedchem.6b00372

Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials

Renee Bouley, Derong Ding, Zhihong Peng, Maria Bastian, Elena Lastochkin, Wei Song, Mark A. Suckow, Valerie A. Schroeder, William R. Wolter, Shahriar Mobashery, Mayland Chang

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core. This discovery was made by in silico screening of 1.2 million compounds for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus. The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class. Eleven promising compounds were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compound 27. This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.

Original language	English
Pages (from-to)	5011-5021
Number of pages	11
Journal	Journal of Medicinal Chemistry
Volume	59
Issue number	10
DOIs	https://doi.org/10.1021/acs.jmedchem.6b00372
State	Published - May 26 2016

Bibliographical note

Funding Information:
This project is supported by Grant AI116548 from the National Institutes of Health (to M.C.). R.B. was supported by Training Grant T32GM075762 and by an individual Ruth L. Kirschstein National Research Service Award F31AI115851 from the National Institutes of Health and by an American Chemical Society Division of Medicinal Chemistry Predoctoral Fellowship. The antisense strains were generous gifts from Dr. Terry Roemer of Merck.

Publisher Copyright:
© 2016 American Chemical Society.

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.6b00372

Cite this

@article{80a3fc38996a4988aed121a1a71b4c56,

title = "Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials",

abstract = "We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core. This discovery was made by in silico screening of 1.2 million compounds for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus. The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class. Eleven promising compounds were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compound 27. This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.",

author = "Renee Bouley and Derong Ding and Zhihong Peng and Maria Bastian and Elena Lastochkin and Wei Song and Suckow, {Mark A.} and Schroeder, {Valerie A.} and Wolter, {William R.} and Shahriar Mobashery and Mayland Chang",

note = "Funding Information: This project is supported by Grant AI116548 from the National Institutes of Health (to M.C.). R.B. was supported by Training Grant T32GM075762 and by an individual Ruth L. Kirschstein National Research Service Award F31AI115851 from the National Institutes of Health and by an American Chemical Society Division of Medicinal Chemistry Predoctoral Fellowship. The antisense strains were generous gifts from Dr. Terry Roemer of Merck. Publisher Copyright: {\textcopyright} 2016 American Chemical Society.",

year = "2016",

month = may,

day = "26",

doi = "10.1021/acs.jmedchem.6b00372",

language = "English",

volume = "59",

pages = "5011--5021",

number = "10",

}

TY - JOUR

T1 - Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials

AU - Bouley, Renee

AU - Ding, Derong

AU - Peng, Zhihong

AU - Bastian, Maria

AU - Lastochkin, Elena

AU - Song, Wei

AU - Suckow, Mark A.

AU - Schroeder, Valerie A.

AU - Wolter, William R.

AU - Mobashery, Shahriar

AU - Chang, Mayland

N1 - Funding Information: This project is supported by Grant AI116548 from the National Institutes of Health (to M.C.). R.B. was supported by Training Grant T32GM075762 and by an individual Ruth L. Kirschstein National Research Service Award F31AI115851 from the National Institutes of Health and by an American Chemical Society Division of Medicinal Chemistry Predoctoral Fellowship. The antisense strains were generous gifts from Dr. Terry Roemer of Merck. Publisher Copyright: © 2016 American Chemical Society.

PY - 2016/5/26

Y1 - 2016/5/26

N2 - We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core. This discovery was made by in silico screening of 1.2 million compounds for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus. The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class. Eleven promising compounds were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compound 27. This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.

AB - We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core. This discovery was made by in silico screening of 1.2 million compounds for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus. The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class. Eleven promising compounds were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compound 27. This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.

UR - http://www.scopus.com/inward/record.url?scp=84971641200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971641200&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00372

DO - 10.1021/acs.jmedchem.6b00372

M3 - Article

C2 - 27088777

AN - SCOPUS:84971641200

VL - 59

SP - 5011

EP - 5021

IS - 10

ER -

Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this